This refresh
Data-driven refresh September 15, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,226 tickers); 1,727 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top 30 — quality compounders at a fair price
1. ADBE — Adobe Inc. · score 88.9
Software - Application · price $257.76 · 1Y $276.40 · 5Y $404.67 · 10Y $600.31
FCF $10.3b A- · Rev +11.5% B · D/E 0.57 C+ · P/E 14.4x A- · PEG 0.64 A-
Why now. Adobe’s Digital Media subscription engine is the cash‑cow that fuels compounding, delivering 11.5% revenue growth YoY, a rock‑solid 28.7% profit margin and $10.3B of free cash flow. Our Bull Rankings model rates the business at a 88.9 quality‑growth score, with Quality as the strongest pillar, confirming that the earnings engine is both high‑margin and resilient. The thesis rests on the subscription flywheel staying intact, which will keep the compounding engine humming for years to come.
Moat. Adobe’s moat lives in its integrated Creative Cloud suite that locks in photographers, video editors, designers and marketers on multi‑year contracts, creating massive switching costs. The 62.8% ROE reflects pricing power that stems from being the de‑facto platform for digital content creation, a position competitors can’t replicate quickly without massive R&D spend and ecosystem lock‑in.
Risk. The market is already pricing in a near‑term free‑cash‑flow growth rate of 0%, while the stock trades at a 14.4 × P/E with a beta of 1.42, indicating volatility. If Adobe’s subscription renewals slow or macro‑headwinds dent enterprise spend, the implied growth cushion evaporates and the stock could tumble toward its 52‑week low of $190.12. A sustained drop in revenue growth below 8% would confirm the bear case.
Horizon. 1-3 yr $276.40 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $404.67 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $600.31 if current growth sustains into durable earnings power.
2. NBIX — Neurocrine Biosciences, Inc. · score 88.5
Drug Manufacturers - Specialty & Generic · price $150.02 · 1Y $210.79 · 5Y $308.62 · 10Y $457.82
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 21.9x B+ · PEG 0.31 A
Why now. NBIX’s growth engine is anchored by INGREZZA, the market‑leading therapy for tardive dyskinesia, which fuels a 34.4% revenue growth and a 20.9% profit margin while generating $870 m of free cash flow. The Bull Rankings model scores Growth at 96, making the compounding power of these products the single most compelling reason to own now, and the 1‑yr consensus target of $210.79 reflects that momentum. The thesis rests on sustaining this high‑growth pipeline and expanding market share in neurological and endocrine disorders.
Moat. INGREZZA and Orilissa are protected by robust FDA‑approved indications and specialty‑care prescribing patterns, creating high switching costs for neurologists and gynecologists who rely on proven efficacy. This IP‑driven exclusivity, combined with a 19.1% ROE derived from pricing power in niche therapeutic categories, gives NBIX a durable competitive edge that rivals cannot quickly replicate.
Risk. The market is pricing NBIX at a lofty PE of 21.9 despite a reverse‑DCF that assumes only a 7% FCF growth start, well below the 34.4% revenue surge, indicating optimism may be overstated; any slowdown in pipeline approvals or a missed sales target for INGREZZA would force the valuation down. A confirming bear signal would be a quarterly earnings miss that pushes the PE above 25 and triggers a sell‑off.
Horizon. 1-3 yr $210.79 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $308.62 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $457.82 if current growth sustains into durable earnings power.
3. HRMY — Harmony Biosciences Holdings, Inc. · score 88.1
Biotechnology · price $42.17 · 1Y $47.36 · 5Y $69.35 · 10Y $102.87
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 13.6x A- · PEG 0.49 A
Why now. The bull case hinges on WAKIX’s monopoly in the U.S. narcolepsy market, where its novel mechanism commands premium pricing and drives a 24.3% revenue growth YoY. Coupled with a solid 18.9% profit margin and a free‑cash‑flow generation of $355 m, the business is already delivering cash‑rich growth that the Bull Rankings model rewards – our Quality‑Growth score of 88.1 reflects a strong Value pillar, confirming the stock is undervalued relative to peers. The thesis rests on sustaining this margin‑rich revenue expansion as WAKIX expands into new indications.
Moat. WAKIX’s patented pitolisant chemistry and FDA‑approved status create a high switching cost for narcolepsy patients and neurologists, shielding the business from generic intrusion. The drug’s unique histamine‑H3 antagonism gives Harmony pricing power in a niche but growing rare‑disease segment, translating into the observed 18.9% margin and a ROE of 18.1% that stems from this protected pricing advantage.
Risk. The bear case centers on execution risk in Harmony’s pipeline – Phase 3 for Prader‑Willi Syndrome and Phase 2 for Myotonic Dystrophy must succeed or the growth engine stalls, while the reverse‑DCF shows the current price assumes a steep -16% FCF decline in year 1, far below the 24.3% revenue growth rate, indicating optimism may be over‑priced. A miss in any trial would force the stock to re‑price to a more modest growth outlook, confirming the downside.
Horizon. 1-3 yr $47.36 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $69.35 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $102.87 if current growth sustains into durable earnings power.
4. DLO — DLocal Limited · score 88
Software - Infrastructure · price $14.45 · 1Y $18.70 · 5Y $27.38 · 10Y $40.61
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 21.3x B+ · PEG 0.62 A-
Why now. DLocal’s global pay‑in platform for merchants—especially its dLocal for Platforms suite—captures the explosive 46.6% revenue growth from cross‑border e‑commerce, while generating $413 m of free cash flow and delivering a stellar 34.6% ROE. The combination of a PEG of 0.62 and a modest beta of 0.87 shows the market is undervaluing a business that can keep compounding on its payment‑method network. The thesis hinges on the platform’s ability to keep expanding its APM coverage, which fuels the same high‑margin growth cycle.
Moat. The platform’s breadth of 100+ alternative payment methods creates a switching cost for merchants who need a single integration to reach local cards, bank transfers and cash—an ecosystem that rivals cannot replicate quickly. This network effect, together with pricing power that yields a 34.6% ROE, locks in recurring transaction fees and high‑margin pay‑out services.
Risk. The Bull Rankings model flags dilution risk and a reverse‑DCF that assumes an initial –8% FCF contraction, far below the 46.6% revenue surge, suggesting the current price may already embed optimism; a miss on growth or a share‑issuance would push the P/E 21.3× even higher and erode margins. A bear would see the stock slide back toward its 52‑week low of $10.64 if the growth rate stalls and dilution accelerates.
Horizon. 1-3 yr $18.70 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $27.38 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $40.61 if current growth sustains into durable earnings power.
5. NVDA — NVIDIA Corporation · score 86.4
Semiconductors · price $212.17 · 1Y $328.66 · 5Y $481.19 · 10Y $713.82
FCF $127.0b A · Rev +83.4% A · D/E 0.17 B+ · P/E 26.8x B · PEG 0.46 A
Why now. NVDA’s AI‑centric Compute & Networking platform is exploding, driven by data‑center customers that are pouring money into accelerated computing. The business is delivering 83.4% revenue growth YoY, 63.7% profit margin, and an eye‑popping 84.2% ROE, all while the Bull Rankings model awards a 86.4/100 quality‑growth score with Growth as its strongest pillar. This combination of runaway top‑line expansion and unmatched profitability means the compounding engine in the data‑center segment will keep powering earnings for years to come – the entire thesis rests on that relentless AI spend.
Moat. The moat lives in NVDA’s proprietary GPU architecture and AI software stack that power the Compute & Networking segment, locking in hyperscale cloud providers and enterprise AI labs that face massive switching costs. The 84.2% ROE reflects pricing power from being the de‑facto standard for AI acceleration, a position competitors can’t replicate quickly without years of R&D and ecosystem development.
Risk. The stock trades at a lofty PE of 26.8 and a beta of 2.22, exposing it to market volatility and a valuation that already assumes a 47% year‑1 FCF growth that may be hard to sustain if AI spend cools. A slowdown in data‑center demand or a breakthrough from rivals would compress margins and force the price back toward fundamentals. The bear case is confirmed if the 52‑week low of $164.27 is breached and the consensus 1‑yr target stalls.
Horizon. 1-3 yr $328.66 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $481.19 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $713.82 if current growth sustains into durable earnings power.
6. PGY — Pagaya Technologies Ltd. · score 86.1
Software - Infrastructure · price $21.04 · 1Y $28.91 · 5Y $42.33 · 10Y $62.79
FCF $252m C · Rev +25.6% A- · D/E 1.34 C · P/E 14.9x A- · PEG 0.04 A
Why now. The bull case hinges on Pagaya’s Decline Monetization engine, which turns rejected loan applications into revenue‑generating assets and is now scaling at 25.6% YoY revenue growth. That growth fuels a robust $252 m free‑cash‑flow run‑rate and, combined with a rock‑bottom PEG of 0.04 and a modest PE of 14.9, makes the stock dramatically undervalued – the entire thesis rests on the network‑effect of Decline Monetization compounding its cash‑flow advantage.
Moat. Pagaya’s moat derives from the proprietary AI‑driven Decline Monetization network, which locks lenders into a data‑rich, automated pipeline that is costly to replicate. This creates high switching costs and underpins the company’s near‑20% ROE, generated by pricing power in a niche of sophisticated U.S. lenders that value the incremental approvals the platform delivers.
Risk. The bear case centers on the extreme volatility implied by a beta of 5.37 and a debt‑to‑equity of 1.34, which amplify downside in a tightening credit environment. Moreover, the Bull Rankings model’s reverse DCF shows an implied -15% FCF contraction in year 1, far below the reported 25.6% revenue growth, suggesting the current price embeds unrealistic optimism. A sustained earnings miss would validate this risk and crush the valuation premise.
Horizon. 1-3 yr $28.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $42.33 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $62.79 if current growth sustains into durable earnings power.
7. INOD — Innodata Inc. · score 85.5
Information Technology Services · price $54.37 · 1Y $122.75 · 5Y $179.72 · 10Y $266.60
FCF $184m C · Rev +39.0% A · D/E 0.02 A- · P/E 42.1x C+ · PEG 0.87 B+
Why now. The bull case hinges on Innodata’s Digital Data Solutions (DDS) segment becoming the go‑to source for AI model training data as enterprises race to scale generative AI. The business is delivering 39% revenue growth YoY, backed by a healthy $184 m of free‑cash‑flow and a stellar ROE of 29.1%, which together prove the model can reinvest profitably while funding rapid expansion. The thesis rests on the compounding demand for high‑quality AI training sets that will keep the DDS engine humming for years to come.
Moat. Innodata’s moat stems from the deep integration of its DDS data pipelines and the Synodex platform that converts raw medical records into structured data for insurers—a workflow that is costly to rebuild and creates high switching costs for health‑care clients. The 29.1% ROE reflects pricing power derived from being a trusted provider of mission‑critical AI data, while the low debt‑to‑equity of 0.02 lets the company reinvest cash without leverage constraints, reinforcing its competitive edge.
Risk. The bear case focuses on the lofty valuation: a forward P/E of 42.1 and a beta of 2.88 imply the market is pricing in sustained high growth that the reverse‑DCF shows is already overstated—free‑cash‑flow is assumed to contract at –6% before easing to 3% over ten years. If AI data demand stalls or competitors undercut pricing, the premium multiple will collapse, and the high beta will amplify the downside. A breach of the implied growth trajectory would confirm the risk and bust the bull thesis.
Horizon. 1-3 yr $122.75 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $179.72 at ~27% CAGR — compounding case rests on the competitive position widening. 10 yr $266.60 if current growth sustains into durable earnings power.
8. GDDY — GoDaddy Inc. · score 85
Software - Infrastructure · price $102.38 · 1Y $104.53 · 5Y $153.05 · 10Y $227.04
FCF $1.7b C+ · Rev +7.4% B · D/E n/a · P/E 15.2x A- · PEG 0.68 A-
Why now. The bull case hinges on GoDaddy’s Applications & Commerce suite—especially the high‑margin Websites + Marketing and Managed WordPress platforms—that are fueling a resilient 7.4% revenue growth and a solid 17.8% profit margin. With a free‑cash‑flow generation of $1.7 B and a modest PE of 15.2, the stock trades at a discount to peers, and our model’s strongest pillar—Quality (96/100)—confirms the business’s cash efficiency and pricing power. The thesis rests on the continuation of this margin‑driven growth compounding faster than the modest reverse‑DCF implied FCF decline.
Moat. GoDaddy’s moat stems from its integrated platform that locks small‑business owners into a suite of web‑hosting, e‑commerce, and marketing tools, creating high switching costs and network effects within the Applications & Commerce segment. The recurring subscription model and deep integration of Managed WordPress with GoDaddy’s domain and hosting services lock in revenue streams that competitors can’t replicate quickly.
Risk. The bear case focuses on the slowing top‑line momentum—revenue growth of only 7.4% YoY—while the reverse‑DCF shows an implied FCF contraction of –14% in year 1, suggesting the market may be over‑optimistic about future cash generation. A further dip in margin or a shift of SMB customers to lower‑cost DIY platforms would pressure the current PE of 15.2, and a sustained decline in FCF growth would trigger a sell‑off. Confirmation would be a miss on the next quarterly revenue growth target, pushing the price toward the 52‑week low of $71.59.
Horizon. 1-3 yr $104.53 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $153.05 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $227.04 if current growth sustains into durable earnings power.
9. APP — AppLovin Corporation · score 84.5
Advertising Agencies · price $331.46 · 1Y $501.94 · 5Y $734.88 · 10Y $1,090
FCF $4.5b B · Rev +60.6% A · D/E 1.11 C+ · P/E 25.5x C+ · PEG 0.70 A-
Why now. The bull case hinges on MAX, AppLovin’s AI‑driven in‑app bidding engine, which is turbo‑charging publisher revenue and fueling a 60.6% YoY revenue growth rate. That growth is underpinned by a $4.5 B free‑cash‑flow haul and a 64.6% profit margin, giving the company a PEG of just 0.7 and a quality‑growth score of 84.5 where Growth is the strongest pillar. The thesis rests on the continuation of this compounding revenue engine as developers double‑down on MAX to capture higher eCPMs.
Moat. MAX creates a real‑time competitive auction that locks publishers into a data‑rich ecosystem, making switching costly because each app’s inventory valuation is calibrated to AppLovin’s AI models. Coupled with Adjust’s measurement platform, developers gain end‑to‑end attribution that only AppLovin can fully integrate, cementing a sticky, high‑margin moat that competitors can’t replicate quickly.
Risk. The bear case centers on the stock’s lofty valuation and volatility: a P/E of 25.5 is premium for a sector where peers trade nearer 15, while a beta of 2.49 amplifies market swings. Moreover, the Bull Rankings model’s reverse‑DCF assumes a 32% FCF growth rate in year 1 that may be unrealistic if revenue growth eases from its current 60.6% pace, and a debt‑to‑equity of 1.11 adds leverage risk. A sustained slowdown in ad spend or a breach in MAX’s auction advantage would trigger a price correction toward the 52‑week low of $297.50.
Horizon. 1-3 yr $501.94 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $734.88 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,090 if current growth sustains into durable earnings power.
10. FICO — Fair Isaac Corporation · score 84.5
Software - Application · price $985.96 · 1Y $1,440 · 5Y $2,109 · 10Y $3,128
FCF $996m C+ · Rev +24.1% A- · D/E n/a · P/E 28.5x B · PEG 0.73 A-
Why now. Software - Application · market cap $21.3b. Down 51% from 52-week high of $1998.01 — deep drawdown territory. Revenue growing +24%, comfortably above the S&P median. PEG 0.73 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $1,440 (implying +46% upside).
Moat. Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. FCF converts 122% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Software economics — recurring revenue, embedded customer workflows, and high gross margin all compound the moat once a base account is won. Switching costs are the lever.
Risk. Down 51% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. ROE -20% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $1,440 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $2,109 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $3,128 if current growth sustains into durable earnings power.
11. DOCS — Doximity, Inc. · score 83.9
Health Information Services · price $25.81 · 1Y $29.94 · 5Y $43.84 · 10Y $65.04
FCF $306m C · Rev +11.2% B · D/E 0.01 A- · P/E 30.7x B · PEG 0.59 A-
Why now. DOCS’s AI‑driven workflow tool Ask cements its position as the go‑to evidence platform for U.S. physicians, unlocking a compounding revenue engine that is already delivering 11.2% YoY revenue growth, 25.5% profit margin and $306 m of free cash flow. Our Bull Rankings model rates the company 83.9/100 on Quality‑Growth, with Quality (88) as the strongest pillar, indicating a high‑margin, defensible business, while the modest Value score flags upside if the market re‑prices the growth premium. Because the reverse‑DCF implies only an 8% FCF growth start versus the actual 11.2% revenue expansion, the current price already assumes optimism, leaving room for a re‑rating to the consensus 1‑yr target of $29.94.
Moat. The Ask AI assistant is embedded in clinicians’ daily workflow, creating a sticky, HIPAA‑compliant platform that physicians cannot easily replace without losing access to curated evidence and peer‑validated content. This network effect, combined with Doximity’s 25‑plus million U.S. medical professional members, generates pricing power reflected in an ROE of 18.2% and a profit margin above 25%, reinforcing a durable moat.
Risk. A 30.7× P/E and a beta of 1.25 signal that the stock is priced for growth and is vulnerable to market pull‑backs; the model’s weak Value pillar (79) warns that any slowdown in revenue growth below the current 11.2% or a margin compression would force a re‑rating. A breach of the 52‑week low at $17.15 or a missed consensus 1‑yr target would confirm the bear case.
Horizon. 1-3 yr $29.94 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $43.84 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $65.04 if current growth sustains into durable earnings power.
12. CARG — CarGurus, Inc. · score 83.6
Internet Content & Information · price $35.00 · 1Y $42.00 · 5Y $61.49 · 10Y $91.22
FCF $315m C · Rev +13.9% B+ · D/E 0.70 B · P/E 18.0x B · PEG 0.74 A-
Why now. CarGurus’ Digital Deal platform is unlocking a new, high‑margin revenue stream by moving the car‑buying process online, and that engine is already humming at 13.9% revenue growth YoY, 18.2% profit margin, and a staggering 66.6% ROE. Those fundamentals sit under a current price of $35, yet analysts collectively see a $42 consensus target, implying the market is already pricing a near‑term upside. The thesis rests on the continuation of Digital Deal’s adoption, which should keep compounding growth well above the modest 4% free‑cash‑flow decline baked into our reverse‑DCF.
Moat. The moat lives in CarGurus’ integrated dealer‑subscription ecosystem and its Digital Deal workflow, which lock both shoppers and dealers into a data‑rich, end‑to‑end buying experience that rivals can’t replicate without massive inventory and partnership build‑out. This lock‑in fuels the extraordinary 66.6% ROE, reflecting pricing power that stems from being the primary online gateway for millions of car shoppers.
Risk. The biggest headwind is the looming slowdown in free‑cash‑flow growth – our reverse‑DCF shows a negative 4% start, far below the 13.9% revenue growth rate, meaning any dip in dealer subscriptions or ad spend would force the price down. A rising debt‑to‑equity of 0.7 combined with a beta of 1.16 amplifies sensitivity to a credit‑tightening cycle, and a breach of the 52‑week low ($26.39) would confirm the market’s fear of margin compression.
Horizon. 1-3 yr $42.00 (analyst consensus (n=12)) — fundamentals + valuation re-rating. 5 yr $61.49 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $91.22 if current growth sustains into durable earnings power.
13. EXLS — ExlService Holdings, Inc. · score 82.3
Information Technology Services · price $36.29 · 1Y $44.63 · 5Y $65.34 · 10Y $96.92
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 23.0x B+ · PEG 0.95 B+
Why now. Our Bull Rankings model gives EXLS an 82.3 quality‑growth score, with Growth as the strongest pillar, because its AI‑driven claims management and underwriting solutions in the Insurance segment are scaling at 13.4% YoY revenue growth while delivering 32.3% ROE and $297m of free cash flow. This combination of high returns and accelerating top‑line compounding fuels a durable earnings runway, and the thesis hinges on the continued capture of AI‑enabled digital operations across insurance and healthcare.
Moat. EXLS locks in large insurers and health plans with integrated AI analytics that automate claims processing, premium administration and actuarial modeling—functions that are costly to replace and embed deep data‑ownership. This creates high switching costs and lets the firm command pricing power, which is reflected in its >30% ROE, far above sector averages.
Risk. The Bull Rankings model flags Value as the weakest pillar; the current price embeds a reverse‑DCF implied FCF growth of 5% fading to 3%, which is below the historical 13.4% revenue expansion and suggests optimism is already priced in. A slowdown in AI adoption or a rise in the debt‑to‑equity ratio (currently 0.57) could pressure the 23× P/E, and a miss on growth would trigger a sell‑off. The bear case materializes if FCF growth stalls below 3% and the stock trades down toward its 52‑week low of $24.85.
Horizon. 1-3 yr $44.63 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $65.34 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $96.92 if current growth sustains into durable earnings power.
14. KTB — Kontoor Brands, Inc. · score 82.2
Apparel Manufacturing · price $67.00 · 1Y $97.50 · 5Y $142.75 · 10Y $211.76
FCF $422m C · Rev +34.3% A · D/E 2.06 C+ · P/E 13.6x B+ · PEG 0.55 A-
Why now. Apparel Manufacturing · market cap $3.7b. Down 25% from 52-week high of $88.96 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. PEG 0.55 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $97.50 (implying +46% upside).
Moat. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 158% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. D/E 2.06 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
Horizon. 1-3 yr $97.50 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $142.75 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $211.76 if current growth sustains into durable earnings power.
15. LRN — Stride, Inc. · score 82.2
Education & Training Services · price $83.56 · 1Y $96.09 · 5Y $140.69 · 10Y $208.71
FCF $433m C · Rev +4.7% C+ · D/E 0.33 A- · P/E 11.7x A- · PEG 0.45 A
Why now. The Bull Rankings model gives LRN an 82.2/100 quality‑growth score, with Value as its strongest pillar, because the platform’s $433 m of free‑cash‑flow and a rock‑solid PE of 11.7x make it dramatically cheap for a company delivering high‑margin software‑engineer and healthcare curricula. Coupled with a ROE of 20.7%, the business can reinvest cash into expanding state‑customized courses while buying back shares, driving upside. The thesis rests on the platform’s ability to keep scaling its curriculum‑as‑a‑service model beyond the modest 4.7% revenue growth rate.
Moat. LRN’s end‑to‑end education platform—single sign‑on, learning‑management, student‑information and analytics—all bundled for state‑customized curricula creates a high switching cost for school districts and workforce‑training programs. That lock‑in fuels the 20.7% ROE, reflecting pricing power from being the default provider of accredited software‑engineering and medical tracks in public‑sector contracts.
Risk. The Bull Rankings model flags Growth as the weakest pillar, and the 4.7% YoY revenue growth starkly trails the reverse‑DCF implied cash‑flow contraction of –11% in year 1, suggesting the market is already pricing in a slowdown; any further deceleration or loss of state contracts would compress margins and erode the 13.4% profit margin. A breach of the 52‑week high‑to‑low gap (current $83.56 vs $155.06) would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $96.09 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $140.69 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $208.71 if current growth sustains into durable earnings power.
16. DECK — Deckers Outdoor Corporation · score 81.3
Footwear & Accessories · price $77.51 · 1Y $120.41 · 5Y $176.29 · 10Y $261.52
FCF $1.1b C+ · Rev +7.9% B · D/E 0.21 A- · P/E 11.0x A- · PEG 0.99 B+
Why now. The HOKA performance‑footwear franchise is poised to accelerate earnings as its premium running and trail shoes capture growing athleisure demand, driven by 7.9% revenue growth YoY, a rock‑solid 18.4% profit margin, and a stellar 44.1% ROE. Management’s aggressive share‑repurchase program further amplifies per‑share earnings, making the current $77.51 price a deep discount to the upside. The thesis hinges on HOKA’s ability to sustain its margin‑rich growth trajectory.
Moat. Deckers leverages the category leadership of HOKA and UGG to command pricing power, reflected in a 44.1% ROE, because retailers and consumers are locked into premium‑priced, differentiated designs that competitors cannot replicate quickly. The diversified brand portfolio across footwear, apparel, and accessories also spreads risk and deepens shelf‑space in key retail channels.
Risk. A bearish view points to the reverse‑DCF implying an initial -5% free‑cash‑flow growth, far below the 7.9% revenue expansion, suggesting the market may be over‑optimistic; combined with a beta of 1.15 and the stock hovering at its 52‑week low of $77.36, any slowdown in HOKA’s momentum would pressure the valuation. A sustained miss on growth would trigger a sell‑off, confirming the bear case.
Horizon. 1-3 yr $120.41 (analyst consensus (n=22)) — fundamentals + valuation re-rating. 5 yr $176.29 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $261.52 if current growth sustains into durable earnings power.
17. ADMA — ADMA Biologics, Inc. · score 81.2
Biotechnology · price $8.61 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $116m C · Rev +8.0% B · D/E 1.11 C · P/E 12.3x A · PEG 0.67 A-
Why now. ADMA’s dominant position in the U.S. plasma‑derived IVIG market fuels a compounding revenue engine anchored by BIVIGAM and ASCENIV, which together drive an 8% revenue growth YoY and a 33% profit margin. The business’s 41.4% ROE reflects pricing power and efficient manufacturing, underpinning our model's strong Quality pillar (83/100). A robust $116 m free‑cash‑flow enables ongoing buybacks that compress share count. The thesis hinges on the continued expansion of immune‑deficiency therapy demand, which sustains earnings growth well beyond the modest 1% reverse‑DCF implied rate.
Moat. ADMA’s moat stems from its integrated plasma collection and bio‑manufacturing platform that supplies proprietary IVIG products to hospitals and specialty clinics, creating high switching costs for clinicians accustomed to its dosing protocols. The 41.4% ROE is underpinned by pricing leverage in a fragmented market where few competitors can match ADMA’s scale and regulatory approvals, locking in a durable cash‑flow advantage.
Risk. The bear case highlights the Bull Rankings model signal that earnings outpace cash, raising questions about the quality of reported profits, especially given the modest 8% revenue growth, which our model identifies as its weakest pillar (Growth 77/100). A debt‑to‑equity of 1.11 adds leverage risk if reimbursement pressures tighten, and the stock trades at a low 12.3× P/E despite a 52‑week low of $7.21, indicating limited upside if the IVIG market contracts. A breach of the 52‑week high at $20.46 would confirm the bullish narrative; failure to breach $12 (the low end of the analyst target range) would validate the downside.
Horizon. 1-3 yr $17.00 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
18. DXCM — DexCom, Inc. · score 79.8
Medical Devices · price $86.45 · 1Y $94.12 · 5Y $137.80 · 10Y $204.42
FCF $1.4b C+ · Rev +15.5% B+ · D/E 0.53 B · P/E 34.2x C+ · PEG 1.28 B
Why now. The Bull Rankings model gives DexCom a Quality‑growth score of 79.8, anchored by a Quality pillar of 90 – the strongest in the suite – because its G7 CGM platform dominates the U.S. continuous glucose monitoring market. The business is delivering 15.5% revenue growth YoY, 20.1% profit margin and a stellar 38.1% ROE, all while the market still values it at a 34.2× PE, leaving ample upside. The thesis rests on the compounding power of the G7 ecosystem expanding into the 15‑day sensor and the Stelo pre‑diabetes line, which should keep growth above 15% for years to come.
Moat. DexCom’s moat stems from its integrated CGM ecosystem – the G7 hardware paired with Dexcom Share and the Follow app – which creates high switching costs for endocrinologists and patients. This lock‑in, combined with a pricing premium that fuels a 38.1% ROE, is underpinned by FDA‑cleared technology that competitors cannot replicate quickly, preserving its category leadership.
Risk. The bear case focuses on the lofty valuation: a 34.2× PE and a beta of 1.42 signal market optimism that may be over‑priced, especially as the reverse‑DCF implies a 22% FCF growth rate in year 1 that far outpaces the actual 15.5% revenue growth. A slowdown in CGM adoption or a successful rival launch could compress margins and push the debt‑to‑equity ratio above its current 0.53, confirming the downside.
Horizon. 1-3 yr $94.12 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $137.80 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $204.42 if current growth sustains into durable earnings power.
19. MELI — MercadoLibre, Inc. · score 79.8
Internet Retail · price $1828.94 · 1Y $2,265 · 5Y $3,316 · 10Y $4,919
FCF $12.4b A- · Rev +41.2% A · D/E 1.69 C+ · P/E 49.9x D · PEG 0.92 B+
Why now. The bull case hinges on Mercado Pago’s expanding financial services moat, which is fueling a virtuous cycle of commerce and payments across Brazil, Mexico, and Argentina. Revenue is surging +41.2% YoY, free cash flow tops $12.4 B, and ROE sits at a lofty 23.8%, all underscoring the compounding power of the payments‑plus‑e‑commerce platform. As long as Mercado Pago continues to lock in merchants and consumers, that growth engine stays lit.
Moat. MELI’s moat lives in its integrated Marketplace‑to‑Pago ecosystem: sellers on Mercado Libre must use Mercado Pago, creating sticky payment data and cross‑selling opportunities for Mercado Credito and Mercado Fondo. This network effect drives pricing power, reflected in a ROE above 20%, and is hard for rivals to replicate without building a comparable user‑base and credit infrastructure.
Risk. The bear case centers on the lofty valuation and leverage: a forward P/E of 49.9× and debt‑to‑equity of 1.69 leave little margin for error if revenue growth eases or margins compress. The Bull Rankings model’s reverse DCF assumes an initial -8% FCF growth, far below the current 41% revenue surge, meaning the market is already pricing in a sharp slowdown. A miss on growth or a rise in financing costs would validate this risk.
Horizon. 1-3 yr $2,265 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,316 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $4,919 if current growth sustains into durable earnings power.
20. RMD — ResMed Inc. · score 79.8
Medical Instruments & Supplies · price $229.44 · 1Y $246.44 · 5Y $360.81 · 10Y $535.24
FCF $1.6b C+ · Rev +9.9% B · D/E 0.13 B+ · P/E 22.0x B+ · PEG 1.29 B
Why now. ResMed’s AirView cloud platform cements its Sleep and Breathing Health segment as the engine of recurring revenue, driving a 9.9% YoY revenue growth while delivering a 26.9% profit margin and a robust $1.6B free‑cash‑flow. Coupled with a dividend raise and a 23.1% ROE, the business compounds earnings at a rate that outpaces peers, making the current price a launchpad for continued compounding. The thesis rests on the platform’s ability to lock in clinics and hospitals with cloud‑connected diagnostics that are hard to replace.
Moat. AirView’s cloud‑connected diagnostics create high switching costs for sleep clinics and hospitals, locking them into ResMed’s data ecosystem and service contracts. This sticky revenue stream fuels a 23.1% ROE, reflecting pricing power from category leadership in home‑based sleep apnea solutions that competitors cannot replicate quickly.
Risk. The market is pricing in a premium P/E of 22 and a PEG of 1.29, suggesting expectations of faster growth than the 9.9% revenue pace can sustain; any slowdown or margin compression would expose the stock to a sharp re‑rating. A breach below the 52‑week low of $180.27 or a failure to meet the analyst consensus target of $246.44 would confirm the over‑optimism and trigger a sell‑off.
Horizon. 1-3 yr $246.44 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $360.81 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $535.24 if current growth sustains into durable earnings power.
21. CPAY — Corpay, Inc. · score 79.5
Software - Infrastructure · price $407.75 · 1Y $461.00 · 5Y $674.95 · 10Y $1,001
FCF $1.6b C+ · Rev +20.4% A- · D/E 2.75 D · P/E 24.8x B+ · PEG 0.78 A-
Why now. Corpay’s corporate‑payments platform is exploding as global firms demand seamless cross‑border spend management, and the business is delivering 20.4% revenue growth while preserving a 22.7% profit margin and a stellar 32.2% ROE. The Bull Rankings model awards a 79.5 quality‑growth score, with Growth as its strongest pillar, confirming that the spend‑management engine will keep compounding. The thesis hinges on the continued rollout of virtual‑card and AP‑modernization solutions that should keep the revenue runway alive for years to come.
Moat. Corpay’s moat lives in its integrated corporate‑payments suite – virtual cards, cross‑border payments and T&E solutions – that lock large enterprises into a single spend‑control ecosystem, creating high switching costs. The 32.2% ROE reflects pricing power derived from category leadership in corporate expense automation, a space where rivals must rebuild compliance and integration capabilities from scratch.
Risk. The biggest headwind is the premium valuation: a forward P/E of 24.8 is well above the sector average, and the Bull Rankings model flags Value as the weakest pillar, suggesting the market may be over‑paying for growth that could decelerate. If revenue growth falls below the current 20.4% pace, the implied 3% free‑cash‑flow growth in the reverse‑DCF becomes untenable, and the stock could tumble toward its 52‑week low of $252.84. A sustained slowdown in corporate spend would confirm the bear case.
Horizon. 1-3 yr $461.00 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $674.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $1,001 if current growth sustains into durable earnings power.
22. BSX — Boston Scientific Corporation · score 79.3
Medical Devices · price $43.87 · 1Y $62.00 · 5Y $90.77 · 10Y $134.66
FCF $3.6b B · Rev +13.5% B+ · D/E 0.50 B · P/E 17.8x A- · PEG 0.63 A-
Why now. Boston Scientific’s dominant position in the endoscopic and cardiovascular device markets will drive compounding earnings as its MedSurg segment expands, powered by a 13.5% revenue growth rate and a robust 17.5% profit margin. The company’s free cash flow of $3.6 B underpins a disciplined buy‑back program that will boost EPS, while a PEG of 0.63 signals that the market is undervaluing this growth. The thesis rests on the Bull Rankings model’s strongest pillar – Growth – delivering sustained top‑line momentum that outpaces the modest -2% reverse‑DCF start‑rate, meaning the upside is already under‑priced.
Moat. BSX’s moat lies in its proprietary endoscopic platforms—single‑use duodenoscopes, SpyGlass and biliary stent systems—that hospitals adopt for high‑volume GI procedures, creating switching costs and a recurring revenue stream. Its Cardiovascular segment leverages deep IP in minimally invasive valve and rhythm‑management devices, allowing pricing power that fuels a 14.7% ROE despite only a 0.5 debt‑to‑equity ratio.
Risk. The bear case centers on the concentration of revenue in the MedSurg segment, where competitive pressure from lower‑cost manufacturers could compress margins; the current P/E of 17.8, while modest, already reflects optimism, and any slowdown from the 13.5% growth rate would expose the stock to a valuation reset. A breach of the reverse‑DCF implied -2% growth in year 1 would confirm the downside and invalidate the growth premium.
Horizon. 1-3 yr $62.00 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $90.77 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $134.66 if current growth sustains into durable earnings power.
23. YUMC — Yum China Holdings, Inc. · score 78.2
Restaurants · price $41.69 · 1Y $61.91 · 5Y $90.65 · 10Y $134.47
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 15.3x B+ · PEG 0.96 B+
Why now. Yum China’s KFC and Pizza Hut brands dominate fast‑food dining in China’s tier‑1 and tier‑2 cities, and the company is rapidly scaling its online delivery platform – a growth engine that delivered 8.8% revenue growth YoY and generated $940 m of free‑cash‑flow over the trailing twelve months. Coupled with a solid 7.8% profit margin and a PEG of 0.96, the Bull Rankings model rates its Quality at 85 (its strongest pillar), implying the business can sustain earnings power while the market still undervalues the upside. The reverse‑DCF shows the current price assumes only ~4% FCF growth, well below the 8.8% revenue pace, so the stock is priced for pessimism – the thesis rests on the price correcting to the analyst consensus $61.91 target.
Moat. The moat lives in Yum China’s exclusive franchise rights to KFC, Pizza Hut, Taco Bell and other concepts, giving it a built‑in distribution network of over 10,000 outlets and a proprietary delivery logistics platform that rivals pure‑play apps. This scale fuels an ROE of 18.2%, driven by pricing power in a market where few competitors can match its supply chain depth and localized menu innovation.
Risk. The bear case centers on the modest growth ceiling: revenue is only expanding at 8.8% YoY while the Chinese quick‑service market is saturating, and the stock now trades just 28% below its 52‑week high of $58.39, suggesting limited upside room. If margin pressure intensifies or the online delivery spend fails to accelerate, the implied 4% FCF growth in the reverse‑DCF would be overstated, and a breach of the $40.15 52‑week low would confirm the downside.
Horizon. 1-3 yr $61.91 (analyst consensus (n=20)) — fundamentals + valuation re-rating. 5 yr $90.65 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $134.47 if current growth sustains into durable earnings power.
24. VRT — Vertiv Holdings Co · score 77.9
Electrical Equipment & Parts · price $234.61 · 1Y $338.15 · 5Y $495.09 · 10Y $734.43
FCF $2.9b B · Rev +26.2% A- · D/E 0.70 B · P/E 53.1x C · PEG 0.80 A-
Why now. Vertiv’s leadership in mission‑critical power and thermal management for data centers fuels a compounding revenue surge of 26.2% YoY, while its free‑cash‑flow generation of $2.9 B and a rock‑solid ROE of 36.4% give the balance sheet the firepower to reinvest and capture share‑of‑wallet. Our Bull Rankings model awards a Quality‑Growth score of 77.9, with Growth as the strongest pillar, underscoring that the business’s compounding engine is the dominant driver. The thesis rests on continued global data‑center expansion that keeps Vertiv’s power‑and‑cooling solutions in relentless demand.
Moat. Vertiv’s integrated modular UPS, AC/DC power management and liquid‑cooled thermal systems lock customers into long‑term service contracts and high switching costs, because data‑center operators cannot afford downtime. The 36.4% ROE reflects pricing power derived from being the go‑to supplier for mission‑critical infrastructure across the Americas, EMEA and APAC, a position competitors cannot replicate quickly.
Risk. The stock trades at a lofty P/E of 53.1 and a beta of 2.08, implying the market already prices in a near‑term free‑cash‑flow growth of ~39% that outpaces the actual revenue growth of 26.2%; any slowdown or margin compression would expose the valuation gap. A modest debt‑to‑equity of 0.7 could balloon if capex spikes, and a pull‑back in data‑center spending would hit the core power‑and‑cooling segment hard. Confirmation of the bear case would be a miss on quarterly revenue growth or a widening of the P/E gap.
Horizon. 1-3 yr $338.15 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $495.09 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $734.43 if current growth sustains into durable earnings power.
25. AVGO — Broadcom Inc. · score 77.7
Semiconductors · price $339.27 · 1Y $531.85 · 5Y $778.68 · 10Y $1,155
FCF $39.4b A · Rev +48.7% A · D/E 0.60 C+ · P/E 43.3x C+ · PEG 0.34 A
Why now. Broadcom’s unrivaled position in custom silicon for data‑center networking fuels a revenue surge of 48.7% YoY, while its 42.9% profit margin and $39.4 B free‑cash‑flow underpin a cash‑rich growth engine. The Bull Rankings model scores a 95 on Growth – the strongest pillar – confirming that the compounding power of its Semiconductor Solutions segment will keep earnings expanding. The thesis hinges on sustaining this high‑margin, high‑growth runway.
Moat. AVGO’s moat lives in its deep integration with hyperscale cloud providers via custom Ethernet switching, routing and NIC silicon, creating multi‑year design wins that lock in revenue and lock out rivals. Its ROE of 38.4% reflects pricing power derived from being the de‑facto supplier for high‑performance data‑center infrastructure, a market where switching costs and design validation barriers are prohibitive.
Risk. The bear case centers on the lofty PE of 43.3 and a beta of 1.46, indicating that any slowdown in data‑center spend or a pricing squeeze could sharply erode valuation. A modest debt‑to‑equity of 0.6 offers limited cushion if cash flow falters, and a pull‑back in the implied 39% year‑1 FCF growth would validate the over‑optimism baked into the current price. A sustained dip in revenue growth below the 48.7% pace would trigger a re‑rating.
Horizon. 1-3 yr $531.85 (analyst consensus (n=47)) — fundamentals + valuation re-rating. 5 yr $778.68 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $1,155 if current growth sustains into durable earnings power.
26. WMG — Warner Music Group Corp. · score 76.6
Entertainment · price $29.05 · 1Y $36.88 · 5Y $54.00 · 10Y $80.10
FCF $836m C+ · Rev +12.9% B+ · D/E 4.53 D · P/E 23.2x B · PEG 0.52 A-
Why now. Warner Music’s Recorded Music segment is riding a relentless stream of streaming royalties as it expands its catalog of two million compositions, delivering 12.9% revenue growth and a razor‑thin PEG of 0.52. The business’s cash conversion is evident in $836 m of free cash flow and a soaring ROE of 78.7%, which together power a dividend hike and give investors a clear compounding engine. The thesis hinges on the ability of its publishing and recorded‑music franchises to keep feeding that cash‑flow runway.
Moat. WMG’s moat lives in its deep music‑publishing library and exclusive artist contracts that lock in licensing fees across streaming, sync and physical channels—assets that cannot be replicated quickly. That IP base fuels the 78.7% ROE by allowing Warner to command premium rates on its catalog and extract higher margins from its Recorded Music business.
Risk. The stock trades at a forward P/E of 23.2, well above the sector average for a name whose revenue growth is only 12.9% YoY, suggesting valuation compression if growth stalls. A debt‑to‑equity ratio of 4.53 and a beta of 1.3 amplify downside risk, and a pull‑back in streaming royalties would quickly erode the free‑cash‑flow cushion. A breach of the 52‑week high at $35.42 would confirm that the market is over‑paying and could trigger a correction.
Horizon. 1-3 yr $36.88 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $54.00 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $80.10 if current growth sustains into durable earnings power.
27. CI — The Cigna Group · score 76.5
Healthcare Plans · price $288.90 · 1Y $339.36 · 5Y $496.86 · 10Y $737.05
FCF $9.1b B+ · Rev +11.3% B · D/E 0.74 C+ · P/E 11.9x A · PEG 0.79 A-
Why now. Cigna’s Evernorth Pharmacy Benefit Services is riding a 11.3% YoY revenue growth while generating a massive $9.1B free‑cash‑flow run‑rate, giving it the cash to fund expansion and buy‑backs. The stock trades at a modest PE of 11.9 and a sub‑1.0 PEG (0.79), meaning the market already values the growth cheaply. The thesis hinges on Evernorth’s ability to keep scaling its PBM network, turning that cash flow into compounding earnings that push the price toward the analyst consensus of $339.36.
Moat. Evernorth’s integrated pharmacy‑benefit‑management platform locks employers and health plans into a high‑touch network of formulary design, drug utilization review, and specialty pharmacy services, creating switching costs that protect margins. The 16.8% ROE reflects pricing power derived from this whole‑person health model, which competitors can’t replicate quickly without comparable scale and data assets.
Risk. The business’s profit margin is razor‑thin at 2.3% and debt‑to‑equity sits at 0.74, leaving little cushion if claim costs rise or regulatory pressure squeezes pricing. Moreover, our reverse‑DCF shows the current price assumes a -10% FCF growth in year 1, far below the 11.3% revenue growth, indicating the market may be over‑optimistic. A sustained margin compression or a spike in debt servicing would trigger the price to fall back toward the 52‑week low of $239.51.
Horizon. 1-3 yr $339.36 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $496.86 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $737.05 if current growth sustains into durable earnings power.
28. STRL — Sterling Infrastructure, Inc. · score 76.2
Engineering & Construction · price $459.02 · 1Y $876.00 · 5Y $1,283 · 10Y $1,903
FCF $482m C · Rev +60.8% A · D/E 0.24 A- · P/E 33.0x C+ · PEG 0.58 A-
Why now. Sterling’s E‑Infrastructure Solutions segment is locked into the booming e‑commerce distribution‑center and data‑center build‑out wave, driving a staggering 60.8% revenue growth YoY. Coupled with $482 m of free‑cash‑flow and a razor‑thin PEG of 0.58, the business is compounding cash at a rate that outpaces peers, making the current price a launchpad for the next growth surge.
Moat. The company’s blue‑chip clientele—major e‑commerce and data‑center operators—creates high switching costs and pricing power, which fuels an ROE of 31.8%. This premium return stems from its ability to bundle site‑development, utility‑grade power, and logistics expertise into a single contract, a service set that rivals can’t replicate quickly.
Risk. A lofty P/E of 33 and a beta of 1.85 signal that the market has already priced in aggressive growth; any slowdown in the e‑commerce construction pipeline or a dip in margin would leave the stock vulnerable, and a breach of the 52‑week low at $281.58 would confirm the overvaluation thesis.
Horizon. 1-3 yr $876.00 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $1,283 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $1,903 if current growth sustains into durable earnings power.
29. EME — EMCOR Group, Inc. · score 75.8
Engineering & Construction · price $735.52 · 1Y $1,033 · 5Y $1,513 · 10Y $2,244
FCF $1.2b C+ · Rev +18.9% B+ · D/E 0.13 A- · P/E 22.9x B+ · PEG 0.31 A
Why now. EMCOR Group is a compelling growth story, demonstrating exceptional operational leverage in critical infrastructure markets. With revenue growth at 18.9% TTM YoY and a robust profit margin of 7.7%, the company is effectively capitalizing on demand for its specialized electrical and mechanical construction and energy solutions. Our model's strongest pillar, Growth (87/100), confirms this trajectory, further underscored by a remarkably low PEG ratio of 0.31, indicating significant undervaluation for its growth profile. The crux of the thesis rests on EME's ability to continue converting this strong top-line expansion into substantial free cash flow.
Moat. EME's durable edge stems from its deep expertise and comprehensive service offerings in highly specialized and mission-critical areas, such as power transmission, distribution, and generation systems, as well as complex clean-room installations. This technical proficiency and integrated service model—from design and installation to operation and maintenance—creates high switching costs for clients, particularly in demanding environments. Our model's Quality pillar (84/100) reflects this, as evidenced by an outstanding ROE of 35.3%, which we attribute to the pricing power derived from its specialized capabilities and established relationships in these essential infrastructure segments.
Risk. The primary risk for EMCOR Group lies in its exposure to the cyclicality inherent in the Engineering & Construction sector, which could see demand for new projects cool. While our model's Growth pillar is strong, its weakest pillar, Value (59/100), suggests that the current P/E of 22.9 is elevated compared to sector peers, and our reverse DCF implies a demanding 22% FCF growth in year one, fading to 3% by year ten—a starting rate that far exceeds the actual revenue growth and prices in heavy optimism. A concrete signal confirming the bear case would be a significant deceleration in new contract awards for its core building and industrial services, or a sustained contraction in its profit margins.
Horizon. 1-3 yr $1,033 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $1,513 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $2,244 if current growth sustains into durable earnings power.
30. CCK — Crown Holdings, Inc. · score 75
Packaging & Containers · price $112.33 · 1Y $136.57 · 5Y $199.95 · 10Y $296.62
FCF $1.2b C+ · Rev +10.3% B · D/E 1.86 C+ · P/E 16.2x B+ · PEG 0.64 A-
Why now. Crown’s dominance in recyclable aluminum beverage cans fuels a compounding revenue engine, delivering 10.3% YoY growth while generating $1.2 B of free cash flow and a robust 27.3% ROE. The Bull Rankings model awards a 78 Quality score, underscoring the durable pricing power in the Americas Beverage segment, and the stock trades at a modest P/E of 16.2, leaving ample upside. The thesis rests on continued secular demand for sustainable packaging that keeps the growth rate ahead of peers.
Moat. CCK’s moat lies in its integrated aluminum can ecosystem—its proprietary forming and coating lines lock in major soft‑drink and beer customers who face high switching costs due to stringent food‑grade standards and long‑term supply contracts. This segment’s high ROE of 27.3% stems from pricing leverage as the only large‑scale producer of recyclable cans in the United States, a capability rivals cannot replicate quickly.
Risk. The bear case centers on the looming slowdown in beverage volume growth and the company’s leverage; a debt‑to‑equity of 1.86 could strain cash flow if margin pressure intensifies, while the current P/E of 16.2 already reflects optimism about future growth. A sustained dip in revenue growth below 5% or a rise in leverage above 2.0 would validate the risk and trigger a price correction.
Horizon. 1-3 yr $136.57 (analyst consensus (n=14)) — fundamentals + valuation re-rating. 5 yr $199.95 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $296.62 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.